Watch SYRE. Know when insiders buy.
One email the day a filing lands. Free.
SYRE
Spyre Therapeutics, Inc.
92.95
+1.55 +1.70%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
37
FLAG · insiders 25, shorts 48
Insiders, 90 days
−$11M
net selling · 0 buys, 25 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $8.2BP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$178.9MNET CASH —52W 22.18 – 108.92NEXT EARNINGS Nov 3 EST.SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$41.6M | −$36.2M | — | -0.35 | −$69.9M | — | — | Aug 4 |
| Q1 2026 · Mar 31 | — | — | — | −$45.6M | −$69M | — | -0.74 | −$57.4M | — | — | Aug 4 |
| Q4 2025 · Dec 31derived | — | — | — | −$57.2M | −$62.5M | — | — | −$44.6M | — | — | Feb 19 |
| Q3 2025 · Sep 30 | — | — | — | −$56.9M | −$11.2M | — | -0.15 | −$37.1M | — | — | Nov 4 |
| Q2 2025 · Jun 30 | — | — | — | −$41.9M | −$36.7M | — | — | −$46.6M | — | — | Aug 4 |
| Q1 2025 · Mar 31 | — | — | — | −$53.6M | −$44.8M | — | — | −$41M | — | — | Aug 4 |
| Q4 2024 · Dec 31derived | $0 | — | — | −$61.3M | −$56.3M | — | — | −$37.2M | — | — | Feb 19 |
| Q3 2024 · Sep 30 | $0 | — | — | −$55.4M | −$69M | — | 1.06 | −$29.4M | — | — | Nov 4 |
| Q2 2024 · Jun 30 | $0 | — | — | −$44.1M | −$38.8M | — | 0.59 | −$62.2M | — | — | Nov 4 |
| Q1 2024 · Mar 31 | $0 | — | — | −$47.8M | −$43.9M | — | 0.72 | −$28.5M | — | — | Nov 4 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$45.9M | −$63.2M | — | -0.89 | −$31M | $0 | −$31M | Feb 19 |
| Q3 2023 · Sep 30 | $0 | — | — | −$18.3M | −$40.1M | — | 0.86 | −$34.6M | — | — | Nov 18 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $0 | — | −$209.6M | −$155.2M | — | — | −$169.3M | — | — | — | — |
| FY2024 · to Dec 31 | $0 | — | −$208.6M | −$208M | — | — | −$157.4M | $0 | −$157.4M | — | — |
| FY2023 · to Dec 31 | $886K | — | −$242.3M | −$338.8M | -38238.1% | 13.76 | −$99.9M | $0 | −$99.9M | — | — |
| FY2022 · to Dec 31 | $2.3M | — | −$84.8M | −$83.8M | -3598.8% | -24.86 | −$80.1M | $38K | −$80.2M | — | — |
| FY2021 · to Dec 31 | $18.7M | — | −$65.6M | −$65.8M | -351.1% | -25.02 | −$53.7M | $573K | −$54.3M | — | — |
| FY2020 · to Dec 31 | $0 | — | −$81.5M | −$80.9M | — | -1.52 | −$75.8M | $4.3M | −$80.1M | — | — |
Every number comes from Spyre Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.